AAPL327.74+1.15 (+0.35%) ▲|ABBV256.10+2.72 (+1.07%) ▲|ABT99.67-1.99 (-1.96%) ▼|ACN140.86-3.87 (-2.67%) ▼|ADBE227.16-7.58 (-3.23%) ▼|AMAT564.55+38.85 (+7.39%) ▲|AMD544.43+40.86 (+8.11%) ▲|AMGN366.24+2.07 (+0.57%) ▲|AMT163.39-3.67 (-2.20%) ▼|AMZN247.55-2.44 (-0.98%) ▼|AVGO386.50+8.34 (+2.21%) ▲|AXP350.79-1.14 (-0.32%) ▼|BA204.80-4.68 (-2.23%) ▼|BAC61.22+0.80 (+1.32%) ▲|BKNG179.40-0.05 (-0.03%) ▼|BLK1,038.24-15.87 (-1.51%) ▼|BMY60.93+0.77 (+1.28%) ▲|BNY158.89+1.96 (+1.25%) ▲|BRK-B489.65-1.60 (-0.33%) ▼|C132.84+4.12 (+3.20%) ▲|CAT889.97+25.67 (+2.97%) ▲|CL90.50-1.43 (-1.56%) ▼|CMCSA23.81+0.03 (+0.13%) ▲|COF206.22-0.55 (-0.27%) ▼|COP117.50+1.82 (+1.57%) ▲|COST929.22-6.58 (-0.70%) ▼|CRM170.06-3.73 (-2.15%) ▼|CSCO112.18+1.48 (+1.34%) ▲|CVS110.60+2.99 (+2.78%) ▲|CVX191.07+1.36 (+0.72%) ▲|DE586.88+0.88 (+0.15%) ▲|DHR179.01-22.10 (-10.99%) ▼|DIS96.14-0.27 (-0.28%) ▼|DUK125.91+0.06 (+0.05%) ▲|EMR139.26+2.68 (+1.96%) ▲|FDX315.19+8.97 (+2.93%) ▲|GD367.73-2.87 (-0.77%) ▼|GE340.70-0.60 (-0.18%) ▼|GEV1,078.81-0.37 (-0.03%) ▼|GILD130.28-2.93 (-2.20%) ▼|GM79.52+3.72 (+4.91%) ▲|GOOG346.19-5.18 (-1.47%) ▼|GOOGL347.15-4.84 (-1.38%) ▼|GS1,085.56+30.53 (+2.89%) ▲|HD331.60-1.44 (-0.43%) ▼|HON229.86+3.68 (+1.63%) ▲|IBM210.50-2.50 (-1.17%) ▼|INTC105.45+8.39 (+8.64%) ▲|INTU289.92-3.90 (-1.33%) ▼|ISRG350.06-3.11 (-0.88%) ▼|JNJ250.61+1.79 (+0.72%) ▲|JPM345.23+6.36 (+1.88%) ▲|KO81.97-0.15 (-0.18%) ▼|LIN505.03-7.02 (-1.37%) ▼|LLY1,175.41+28.51 (+2.49%) ▲|LMT507.09-2.45 (-0.48%) ▼|LOW203.51-1.20 (-0.59%) ▼|LRCX322.00+15.24 (+4.97%) ▲|MA538.30-9.14 (-1.67%) ▼|MCD263.91-3.73 (-1.39%) ▼|MDLZ59.86-0.41 (-0.68%) ▼|MDT82.35-0.94 (-1.13%) ▼|META643.81-2.04 (-0.32%) ▼|MMM170.76+11.65 (+7.32%) ▲|MO72.99-1.67 (-2.24%) ▼|MRK126.26+1.86 (+1.50%) ▲|MS216.40+5.46 (+2.59%) ▲|MSFT397.75-4.54 (-1.13%) ▼|MU970.82+105.36 (+12.17%) ▲|NEE87.93-0.07 (-0.08%) ▼|NFLX68.67+1.07 (+1.58%) ▲|NKE42.96-0.51 (-1.17%) ▼|NOW102.06-2.64 (-2.52%) ▼|NVDA207.29+4.01 (+1.97%) ▲|ORCL127.05+5.67 (+4.67%) ▲|PEP135.00-0.46 (-0.34%) ▼|PFE24.94+0.19 (+0.77%) ▲|PG148.10-1.03 (-0.69%) ▼|PLTR132.66-2.19 (-1.62%) ▼|PM188.04-4.68 (-2.43%) ▼|QCOM173.50+3.18 (+1.87%) ▲|RTX193.67-0.77 (-0.40%) ▼|SBUX104.45-0.36 (-0.34%) ▼|SCHW99.96-2.58 (-2.52%) ▼|SO93.85-0.61 (-0.65%) ▼|SPG226.79-1.40 (-0.61%) ▼|T22.26+0.31 (+1.41%) ▲|TMO523.46-2.77 (-0.53%) ▼|TMUS190.77-4.87 (-2.49%) ▼|TSLA378.93+9.36 (+2.53%) ▲|TXN291.30+7.23 (+2.55%) ▲|UBER71.55-0.62 (-0.86%) ▼|UNH436.35+14.80 (+3.51%) ▲|UNP293.13-3.12 (-1.05%) ▼|UPS116.34+3.19 (+2.82%) ▲|USB63.71+0.57 (+0.90%) ▲|V355.82-4.75 (-1.32%) ▼|VZ43.78+0.28 (+0.64%) ▲|WFC87.74+1.41 (+1.63%) ▲|WMT110.39-1.81 (-1.61%) ▼|XOM151.71+3.35 (+2.26%) ▲|AAPL327.74+1.15 (+0.35%) ▲|ABBV256.10+2.72 (+1.07%) ▲|ABT99.67-1.99 (-1.96%) ▼|ACN140.86-3.87 (-2.67%) ▼|ADBE227.16-7.58 (-3.23%) ▼|AMAT564.55+38.85 (+7.39%) ▲|AMD544.43+40.86 (+8.11%) ▲|AMGN366.24+2.07 (+0.57%) ▲|AMT163.39-3.67 (-2.20%) ▼|AMZN247.55-2.44 (-0.98%) ▼|AVGO386.50+8.34 (+2.21%) ▲|AXP350.79-1.14 (-0.32%) ▼|BA204.80-4.68 (-2.23%) ▼|BAC61.22+0.80 (+1.32%) ▲|BKNG179.40-0.05 (-0.03%) ▼|BLK1,038.24-15.87 (-1.51%) ▼|BMY60.93+0.77 (+1.28%) ▲|BNY158.89+1.96 (+1.25%) ▲|BRK-B489.65-1.60 (-0.33%) ▼|C132.84+4.12 (+3.20%) ▲|CAT889.97+25.67 (+2.97%) ▲|CL90.50-1.43 (-1.56%) ▼|CMCSA23.81+0.03 (+0.13%) ▲|COF206.22-0.55 (-0.27%) ▼|COP117.50+1.82 (+1.57%) ▲|COST929.22-6.58 (-0.70%) ▼|CRM170.06-3.73 (-2.15%) ▼|CSCO112.18+1.48 (+1.34%) ▲|CVS110.60+2.99 (+2.78%) ▲|CVX191.07+1.36 (+0.72%) ▲|DE586.88+0.88 (+0.15%) ▲|DHR179.01-22.10 (-10.99%) ▼|DIS96.14-0.27 (-0.28%) ▼|DUK125.91+0.06 (+0.05%) ▲|EMR139.26+2.68 (+1.96%) ▲|FDX315.19+8.97 (+2.93%) ▲|GD367.73-2.87 (-0.77%) ▼|GE340.70-0.60 (-0.18%) ▼|GEV1,078.81-0.37 (-0.03%) ▼|GILD130.28-2.93 (-2.20%) ▼|GM79.52+3.72 (+4.91%) ▲|GOOG346.19-5.18 (-1.47%) ▼|GOOGL347.15-4.84 (-1.38%) ▼|GS1,085.56+30.53 (+2.89%) ▲|HD331.60-1.44 (-0.43%) ▼|HON229.86+3.68 (+1.63%) ▲|IBM210.50-2.50 (-1.17%) ▼|INTC105.45+8.39 (+8.64%) ▲|INTU289.92-3.90 (-1.33%) ▼|ISRG350.06-3.11 (-0.88%) ▼|JNJ250.61+1.79 (+0.72%) ▲|JPM345.23+6.36 (+1.88%) ▲|KO81.97-0.15 (-0.18%) ▼|LIN505.03-7.02 (-1.37%) ▼|LLY1,175.41+28.51 (+2.49%) ▲|LMT507.09-2.45 (-0.48%) ▼|LOW203.51-1.20 (-0.59%) ▼|LRCX322.00+15.24 (+4.97%) ▲|MA538.30-9.14 (-1.67%) ▼|MCD263.91-3.73 (-1.39%) ▼|MDLZ59.86-0.41 (-0.68%) ▼|MDT82.35-0.94 (-1.13%) ▼|META643.81-2.04 (-0.32%) ▼|MMM170.76+11.65 (+7.32%) ▲|MO72.99-1.67 (-2.24%) ▼|MRK126.26+1.86 (+1.50%) ▲|MS216.40+5.46 (+2.59%) ▲|MSFT397.75-4.54 (-1.13%) ▼|MU970.82+105.36 (+12.17%) ▲|NEE87.93-0.07 (-0.08%) ▼|NFLX68.67+1.07 (+1.58%) ▲|NKE42.96-0.51 (-1.17%) ▼|NOW102.06-2.64 (-2.52%) ▼|NVDA207.29+4.01 (+1.97%) ▲|ORCL127.05+5.67 (+4.67%) ▲|PEP135.00-0.46 (-0.34%) ▼|PFE24.94+0.19 (+0.77%) ▲|PG148.10-1.03 (-0.69%) ▼|PLTR132.66-2.19 (-1.62%) ▼|PM188.04-4.68 (-2.43%) ▼|QCOM173.50+3.18 (+1.87%) ▲|RTX193.67-0.77 (-0.40%) ▼|SBUX104.45-0.36 (-0.34%) ▼|SCHW99.96-2.58 (-2.52%) ▼|SO93.85-0.61 (-0.65%) ▼|SPG226.79-1.40 (-0.61%) ▼|T22.26+0.31 (+1.41%) ▲|TMO523.46-2.77 (-0.53%) ▼|TMUS190.77-4.87 (-2.49%) ▼|TSLA378.93+9.36 (+2.53%) ▲|TXN291.30+7.23 (+2.55%) ▲|UBER71.55-0.62 (-0.86%) ▼|UNH436.35+14.80 (+3.51%) ▲|UNP293.13-3.12 (-1.05%) ▼|UPS116.34+3.19 (+2.82%) ▲|USB63.71+0.57 (+0.90%) ▲|V355.82-4.75 (-1.32%) ▼|VZ43.78+0.28 (+0.64%) ▲|WFC87.74+1.41 (+1.63%) ▲|WMT110.39-1.81 (-1.61%) ▼|XOM151.71+3.35 (+2.26%) ▲|
23.7 C
New York
Wednesday, July 22, 2026

Tag: trends

newssourceFORcompanyinformationcontent1releasesmarket

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Group 1 Automotive Announces Honda of Owings Mills is now Group 1 Honda Owings Mills

Former Honda of Owings Mills location continues serving Owings Mills and Baltimore County customers under the Group 1 Honda Owings Mills nameOWINGS MILLS, Md.,...

Group 1 Automotive Announces Honda of Greenbelt is now Group 1 Honda Greenbelt

Former Honda of Greenbelt location continues serving Greenbelt and Prince George's County customers under the Group 1 Honda Greenbelt nameGREENBELT, Md., June 26, 2026...

The Doctors Company Completes Acquisition of ProAssurance Corporation

NAPA, Calif., June 26, 2026 /PRNewswire/ -- The Doctors Company, the nation's largest physician-owned medical malpractice insurer, announced today that it has completed the acquisition...

Mediaplanet Launches Women in Computing Campaign to Spotlight the Future of Technology and Empower the Next Generation of Women Leaders

New digital campaign brings together leading organizations, innovators, and advocates to explore opportunities, challenges, and pathways for women pursuing careers in technology.NEW YORK, June...

Mattr Corp. Announces Renewal of Normal Course Issuer Bid

TORONTO, June 26, 2026 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR), today announced that the Toronto Stock Exchange (the “TSX”) has approved the Company’s notice of intention to renew its normal course issuer bid (the “NCIB”) for common shares of the Company (the “Common Shares”).

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

PowerBank Awarded $2,950,000 USD Federal Contract with the US Department of Defense and the Department of the Army for Covered Parking Canopy Solar Project

Project to also include the installation of electric vehicle charging stationsTORONTO, June 26, 2026 /CNW/ - PowerBank Corporation (NASDAQ: PBK) (Cboe CA: PBK) (FSE:...

Co-operators Hosts Auto Theft Prevention Event at Guelph Headquarters

GUELPH, ON, June 26, 2026 /CNW/ - Co-operators brought together community partners, government leaders and employees today at its Guelph headquarters to raise awareness about auto theft and highlight the...

Agricultural Films Market worth $21.6 billion by 2031 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 26, 2026 /PRNewswire/ -- According to MarketsandMarkets™, "Agricultural Films Market by Type (LDPE, LLDPE, EVA, Reclaim, HDPE), Application , and...

Agricultural Films Market worth $21.6 billion by 2031 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 26, 2026 /PRNewswire/ -- According to MarketsandMarkets™, "Agricultural Films Market by Type (LDPE, LLDPE, EVA, Reclaim, HDPE), Application , and...

[Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report,...

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global In Silico Clinical Trials Market size & share revenue was valued at approximately USD 1.84 Billion in 2025 and is expected to reach USD 2.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 15.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Certara Inc., Simulations Plus Inc., Dassault Systèmes SE (SIMULIA/BIOVIA), Ansys Inc., Medidata Solutions (Dassault Systèmes), Insilico Medicine Ltd., Unlearn.AI Inc., Applied BioMath LLC, Rosa & Co. LLC, Entelos Inc., Pharsight Corporation (Certara) and others. 
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global In Silico Clinical Trials Market size & share revenue was valued at approximately USD 1.84 Billion in 2025 and is expected to reach USD 2.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 15.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Certara Inc., Simulations Plus Inc., Dassault Systèmes SE (SIMULIA/BIOVIA), Ansys Inc., Medidata Solutions (Dassault Systèmes), Insilico Medicine Ltd., Unlearn.AI Inc., Applied BioMath LLC, Rosa & Co. LLC, Entelos Inc., Pharsight Corporation (Certara) and others.

Coda and EKRAF Open New Global Pathways for Indonesian Game Developers

This collaboration equips local creative talent with the monetization infrastructure, networks, and market access needed to compete globally.JAKARTA, Indonesia, June 26, 2026 /PRNewswire/ --...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrends

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers